About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 1NCT00519259

Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

The purpose of this study is to assess safety and pharmacokinetics of sublingual lobeline in healthy normal volunteers.

Lead sponsor: National Institute on Drug Abuse (NIDA)•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

National Institute on Drug Abuse (NIDA)

Age

18 - 45 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Must be able to provide written informed consent
•Must have a body mass index between 18 and 30
•Have no medical contraindications as determined by medical history, physical exam, ECG, hematology and blood chemistry profile, and urinalysis
•Must have a negative drug test at screening and admission
•If female of child bearing potential, must agree to use birth control

Exclusion Criteria

•Please contact the site for more information

Related studies

rTMS for Stimulant Use Disorders

NCT04907357 · Cocaine Use Disorder, Methamphetamine Abuse, and more

Risk and Protective Factors for Rural Methamphetamine Dependence

NCT00882037 · Methamphetamine Dependence

COMPLETEDPhase 1

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

NCT01062451 · Methamphetamine Dependence, Methamphetamine Abuse, and more

COMPLETEDPhase 4

Effects of Modafinil in Methamphetamine Dependence

NCT00751023 · Methamphetamine Dependence

COMPLETEDPhase 2

Trial of Ibudilast for Methamphetamine Dependence

NCT01860807 · Methamphetamine Dependence, HIV Infection

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 11, 2017Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE1

Enrollment12

Start dateFeb 2006

Last updatedJan 11, 2017

Condition

Methamphetamine Dependence

Locations shown

Langley Porter Psychiatric Institute

San Francisco, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 11, 2017Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions